Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from stavudine or zidovudine to tenofovir DF in virologically suppressed HIV-infected children
2007-003418-32Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Maintenance of virologic suppression at Week 48. Started Oct 2007; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-003418-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003418-32.